DrugPatentWatch Database Preview

Drugs in Development Information for N91115

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug N91115?

N91115 is an investigational drug.

There have been 8 clinical trials for N91115. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1^st 2019.

The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and Asthma. The leading clinical trial sponsors are Nivalis Therapeutics, Inc., Davita Clinical Research, and University of North Carolina, Chapel Hill.

There are eleven US patents protecting this investigational drug and fifty-nine international patents.

Summary for N91115

US Patents	11
International Patents	59
US Patent Applications	28
WIPO Patent Applications	11
Japanese Patent Applications	3
Clinical Trial Progress	Phase 1 (2019-11-01)
Vendors	8

Recent Clinical Trials for N91115

Title	Sponsor	Phase
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study	University of North Carolina, Chapel Hill	Phase 2
MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)	Nivalis Therapeutics, Inc.	Phase 1

See all N91115 clinical trials

Clinical Trial Summary for N91115

Top disease conditions for N91115

Top clinical trial sponsors for N91115

See all N91115 clinical trials

US Patents for N91115

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
N91115		Solid forms of an S-Nitrosoglutathione reductase inhibitor	LAUREL THERAPEUTICS LTD. (Hangzhou, Zhejiang Province, CN)
N91115		N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease	Novartis AG (Basel, CH)
N91115		Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors	N30 Pharmaceuticals, Inc. (Boulder, CO)
N91115		Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors	N30 Pharmaceuticals, Inc. (Boulder, CO)
N91115		Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors	Nivalis Therapeutics, Inc. (Boulder, CO)

International Patents for N91115

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
N91115	World Intellectual Property Organization (WIPO)	WO2017044766	2035-09-10
N91115	World Intellectual Property Organization (WIPO)	WO2017044788	2035-09-10
N91115	Argentina	AR109437	2036-08-29
N91115	Australia	AU2017319430	2036-08-29
N91115	Brazil	BR112019003883	2036-08-29